|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Abgenix Inc., of Fremont, Calif., entered a collaboration with U3 Pharma AG, of Martinsried, Germany, for fully human monoclonal antibody therapies directed against validated drug targets selected from U3's portfolio. Abgenix will use its XenoMouse and/or XenoMax human antibody technologies to generate and select fully human antibodies against U3 targets. Both parties will conduct in vitro and in vivo studies of the antibody candidates, and will have the right to develop and commercialize antibody products discovered during the collaboration. The parties will share equally in development costs and potential resulting profits.
Advanced Tissue Sciences Inc., of La ...